top of page

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors



Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Upmc Cancercenter, Pittsburgh, Pennsylvania, United States|Md Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|Chris Obrien Lifehouse, Camperdown, New South Wales, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Nucleus Network Pty Ltd, Melbourne, Victoria, Australia|Linear Clinical Research, Nedlands, Western Australia, Australia|Cliniques Universitaires Ucl Saint-Luc, Brussels, Belgium|Institut Jules Bordet Clinical Trials Conduct Unit, Brussels, Belgium|Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium|Ghent University Hospital, Ghent, Belgium|Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium|Complex Onclogy Center Plovdiv Eood, Plovdiv, Bulgaria|Complex Oncological Center - Ruse Eood, Ruse, Bulgaria|Shatod Dr Marko Marko - Varna Ltd, Varna, Bulgaria|Institut de Cancerologie de L Ouest - Site Paul Papin, Angers, France|Institut Bergonie, Bordeaux, France|Chu Hopital de La Timone, Marseille Cedex 5, France|Centre Eugene Marquis, Rennes, France|National Cancer Center Hospital East, Chiba, Japan|National Cancer Center Hospital, Tokyo, Japan|Multifield Clinical Hospital No 4, Dnipro, Ukraine|Ci of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharkiv, Ukraine|Kherson Regional Oncologic Dispensary, Kherson, Ukraine|Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Kryvyi Rih, Ukraine|Volyn Regional Oncological Dispensary, Lutsk, Ukraine|Rmi Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine|Cne Ccch of Uzh Cc Oncological Center, Uzhgorod, Ukraine|Medical Clinic Innovacia Llc, Vyshhorod, Ukraine


Drug: INCB099280

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists


bottom of page